Incidence and risk of colitis with programmed death-1 versus programmed death-ligand 1 inhibitors for the treatment of cancer.

被引：0
|
作者：
Miyashita, Hirotaka
Mikami, Takahisa
Satoi, Sera
Cruz, Christina
Galsky, Matt D.
机构：
[1] Mt Sinai Beth Israel, New York, NY USA
[2] Nippon Med Coll Hosp, Tokyo, Japan
[3] Mt Sinai Hosp, New York, NY 10029 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15087
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer
    Miyashita, Hirotaka
    Mikami, Takahisa
    Satoi, Sera
    Cruz, Christina
    Galsky, Matthew D.
    [J]. JOURNAL OF IMMUNOTHERAPY, 2020, 43 (09) : 291 - 298
  • [2] Targeting the programmed death-1/programmed death-ligand 1 axis in lymphoma
    Cheah, Chan Yoon
    Fowler, Nathan H.
    Neelapu, Sattva S.
    [J]. CURRENT OPINION IN ONCOLOGY, 2015, 27 (05) : 384 - 391
  • [3] Development of Inhibitors of the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Signaling Pathway
    Wang, Tianyu
    Wu, Xiaoxing
    Guo, Changying
    Zhang, Kuojun
    Xu, Jinyi
    Li, Zheng
    Jiang, Sheng
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2019, 62 (04) : 1715 - 1730
  • [4] Programmed Death-1 and Programmed Death-Ligand 1 Expression Patterns in Pediatric Lymphoma
    Tamura, Akihiro
    Yoshida, Makiko
    Yamamoto, Nobuyuki
    Nino, Nanako
    Nakatani, Naoko
    Ichikawa, Takayuki
    Nakamura, Sayaka
    Saito, Atsuro
    Kozaki, Aiko
    Kishimoto, Kenji
    Ishida, Toshiaki
    Hasegawa, Daiichiro
    Kosaka, Yoshiyuki
    [J]. BLOOD, 2018, 132
  • [5] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu Qiang
    Li Chun-Sheng
    [J]. 中华医学杂志(英文版), 2017, (08) : 986 - 992
  • [6] Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis
    Liu, Qiang
    Li, Chun-Sheng
    [J]. CHINESE MEDICAL JOURNAL, 2017, 130 (08) : 986 - 992
  • [7] Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy
    Hamid, Omid
    Carvajal, Richard D.
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2013, 13 (06) : 847 - 861
  • [8] Discovery of the programmed cell death-1/programmed cell death-ligand 1 interaction inhibitors bearing an indoline scaffold
    Qin, Mingze
    Cao, Qi
    Wu, Xia
    Liu, Chunyang
    Zheng, Shuaishuai
    Xie, Hongbo
    Tian, Ye
    Xie, Jun
    Zhao, Yanfang
    Hou, Yunlei
    Zhang, Xian
    Xu, Boxuan
    Zhang, Haotian
    Wang, Xiaobo
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 186
  • [9] Progress in programmed cell death-1/programmed cell death-ligand 1 pathway inhibitors and binding mode analysis
    Li, Xiaoyun
    Zeng, Qin
    Xu, Fengjiao
    Jiang, Yuying
    Jiang, Zhongmei
    [J]. MOLECULAR DIVERSITY, 2023, 27 (04) : 1935 - 1955
  • [10] Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
    Caleb J. Smith
    Yahya Almodallal
    Aminah Jatoi
    [J]. Current Oncology Reports, 2021, 23
12345